Little is known about the alterations in microRNA (miRNA) expression patterns during the consecutive stages of cervical cancer development and their association with chromosomal instability. In this study, miRNA expression in normal cervical squamous epithelium, high-grade precancerous lesions (cervical intraepithelial neoplasia (CIN2 --3)), squamous cell carcinomas (SCCs) and adenocarcinomas (AdCAs) was integrated with previously generated chromosomal profiles of the same samples. Significantly differential expression during the consecutive stages of cervical SCC development was observed for 106 miRNAs. Of these differentially expressed miRNAs, 27 showed early transiently altered expression in CIN2 --3 lesions only, 46 miRNAs showed late altered expression in SCCs only and 33 showed continuously altered expression in both CIN2 --3 and SCCs. Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations. Functional analyses were performed for hsa-miR-9, representing a potential oncogene with increased expression linked to a chromosomal gain of 1q. Hsa-miR-9 overexpression was found to increase cell viability, anchorage-independent growth and migration in vitro. Upon organic raft culturing, hsa-miR-9 hampered differentiation and induced proliferation in all strata of the epithelial layer. These findings support a potential oncogenic function of hsa-miR-9 in cervical cancer. In summary, differential expression of 106 miRNAs, partly associated with chromosomal alterations, was observed during cervical SCC development. Altered expression of hsa-miR-9 associated with a chromosomal gain of chromosome 1q was shown to be functionally relevant, underlining the importance of deregulated miRNA expression in cervical carcinogenesis.
INTRODUCTION
Cervical cancer is caused by a persistent infection with high-risk types of the human papillomavirus (hrHPV). 1, 2 Histologically, cervical cancer can be divided into different subtypes, including squamous cell carcinomas (SCCs; about 80% of cases) and adenocarcinomas (AdCAs; about 5 --20% of cases). 3, 4 Whereas SCCs develop via well-defined precursor stages, called cervical intraepithelial neoplasia (CIN, graded 1 --3), precursor stages for AdCAs are less well characterised. To reflect their relative risk of progression to cervical cancer, CIN1 lesions are nowadays often referred to as low-grade CIN whereas CIN2 and 3 lesions together are considered high-grade CIN. Whereas high-grade CIN can arise rather fast following hrHPV infection (2 --3 years), subsequent development of an invasive carcinoma may take at least one or more decades, 5 --8 indicating that CIN2-3 lesions represent a heterogeneous disease.
Nearly all high-grade CIN lesions (CIN2 --3) and virtually all carcinomas are associated with a so-called transforming hrHPV infection, which is characterised by deregulated expression of the viral oncogenes E6 and E7 in the proliferating (supra)basal cells of the epithelium. Genetic instability due to the presence of a transforming infection can ultimately result in the accumulation of specific (epi)genetic changes in the host-cell genome driving progression to a malignant phenotype.
Although previous studies have identified chromosomal alterations, gene expression changes and aberrant promoter methylation associated with cervical cancer, little is known about the role of microRNAs (miRNAs). Whereas the importance of miRNAs in human carcinogenesis is becoming increasingly recognised, the potential role of miRNAs in cervical cancer development has been demonstrated only in few studies. HPV-encoded genes have been shown to influence the miRNA expression of its host cell. 9 --14 Muralidhar et al. 15, 16 showed that a frequently occurring gain of chromosome 5p in cervical cancer is associated with functionally relevant elevated expression of the miRNA-processing enzyme Drosha, and altered miRNA expression profiles. Furthermore, a panel of miRNAs able to predict cervical cancer survival was recently described. 17 A number of studies have shown altered miRNA expression patterns in cervical-cancer cell lines and cervical-cancer tissues. 18 --21 So far, only limited data on genomewide miRNA expression patterns in CIN lesions is available. 22, 23 As human miRNAs are frequently located at fragile sites and chromosomal regions affected in cancer, 24 chromosomal alterations are thought to represent a major mechanism underlying altered miRNA expression in cancer. Indeed, an association between chromosomal alterations and differential miRNA expression has been described for ovarian cancer, breast cancer, melanoma, neuroblastoma and myeloma cell lines. 25 --28 In cervical cancer we previously showed that particularly gains on chromosomes 1, 3q and 20q may be involved in malignant progression. 29 Integration of chromosomal alterations with miRNA expression may further clarify the functional role of frequent chromosomal alterations and aid in the identification of novel potential tumour suppressors and oncogenes in cervical carcinogenesis.
In this study, we aimed to obtain a comprehensive overview of the alterations in miRNA expression that occur during the progression from normal cervical epithelium, via high-grade CIN lesions, to SCCs and to relate the observed changes in miRNA expression to chromosomal alterations. Genome-wide miRNA expression profiles of micro-dissected specimens of normal squamous epithelium, CIN2 --3, SCCs and AdCAs were obtained and directly integrated with previously generated chromosomal profiles of the same samples. 29, 30 Functional effects of altered expression of hsa-miR-9, which was associated with a frequent chromosomal gain, were further investigated in vitro.
RESULTS

Distinct miRNA expression profiles related to histology
In this study genome-wide miRNA expression profiles were determined in microdissected SCCs (n ¼ 10), AdCAs (n ¼ 9), CIN2 --3 (n ¼ 18) and normal cervical squamous epithelial (n ¼ 10) samples. To obtain an overview of the similarities between the overall miRNA expression profiles, unsupervised hierarchical clustering was performed, resulting in two major clusters ( Figure 1 ). Cluster 1 contained 90% of normal samples, 22% of CIN2 --3 and 10% of SCCs. Cluster 2 contained only one normal sample (10%) and the vast majority of all cervical (pre)malignant lesions (78% of CIN2 --3, 90% of SCCs and 100% of AdCAs). Within cluster 2, separate sub-clusters could be observed. Although one of them (Figure 1 2a) comprises of a mixture of four CIN2 --3, 2 AdCAs and one normal sample, the other sub-clusters contained only AdCAs (Figure 1 2b) , CIN2 --3 ( Figure 1 2c) or SCCs (Figure 1 2d) . The fact that CIN2 --3 lesions are most scattered across the different clusters may reflect the heterogeneity of high-grade CIN disease in general. Our clustering results suggest that miRNA expression in a subset of the CIN lesions is still similar to hrHPV-positive normal epithelium, supporting the observation that CIN2 --3 lesions may take one or two decades to progress into an invasive carcinoma. 5 On the other hand, cluster 2a suggests that another subset of the CIN 2 --3 lesions may resemble AdCAs with respect to their miRNA expression profile. Interestingly, CIN 2 --3 lesions are frequently found adjacent to AdCAs, which may be a result of bidirectional differentiation of hrHPV-infected metaplastic epithelial cells of the transformation zone. 31 Differential miRNA expression related to histology miRNA expression was compared between normal epithelium, CIN2 --3, SCCs and AdCAs. In total, 106 miRNAs were differentially expressed in CIN2 --3 and/or SCCs compared with normal epithelium (Table 1a) , whereas 18 miRNAs were differentially expressed between SCCs and AdCAs (Table 1b) . To verify the reliability of the miRNA arrays we re-analysed the expression of hsa-miR-9/15b/21/28-5p/100/125b/203/375 in 39 of 47 samples analysed by array using quantitative reverse transcription--PCR (qRT--PCR). For all miRNAs, significant correlations between array and qRT--PCR results were found (range 0.67 --0.95; Supplementary  Figure 1 ; Po0.01 for all miRNAs). Fold changes between sample groups detected by qRT--PCR were in general larger than those detected by microarray (Supplementary Figure 2) .
Results of the comparisons involving normal epithelium, CIN2 --3 and SCCs were subsequently combined to determine patterns of differential miRNA expression during cervical SCC development. MiRNAs with significant differential expression in CIN2 --3 compared with normal (false discovery rate (FDR)o0.05) that were unchanged in SCCs compared with normal (FDR40.1) were designated 'early transient' (Figure 2a ; 18 upregulated and 9 downregulated miRNAs). MiRNAs showing significant differential expression in SCCs compared with normal and/or compared with CIN2 --3 (FDRo0.05), but not in CIN2 --3 compared with normal (FDR40.1) were classified as 'late' (Figure 2b ; 27 upregulated and 19 downregulated miRNAs). Finally, 'early continuous' differentially expressed miRNAs (Figure 2c ; 18 upregulated miRNAs and 15 downregulated miRNAs) showed concordant differential expression in SCCs and CIN2 --3 compared with normal (one FDRo0.05 and the other FDRo0.1).
Differential miRNA expression related to chromosomal alterations Differential gene locus mapping analysis (DIGMAP) was applied to compare the expression profiles of all miRNAs present on the array grouped by their chromosomal location between CIN2 --3/SCCs and normal epithelium. This yielded four loci, located at chromosomes 9, 13, 14 and X, exhibiting differential miRNA expression between CIN2 --3/SCCs and normal epithelium ( Table 2 ). The loci on chromosomes 9 and 14 were not positioned in a frequently altered chromosomal region; however, these loci are known to contain clusters of miRNAs located within 10 kb of each other. For chromosome X no chromosomal information was available, but miRNAs in the identified locus on chromosome X are also clustered. Finally, the locus on chromosome 13 showed increased expression of a well-known cluster of onco-miRs (17 --92 cluster) located there, despite the presence of a chromosomal loss. Previously generated genome-wide chromosomal profiles of all CIN2 --3 and SCCs used in this study also enabled us to directly investigate the association between copy number and miRNA expression. Expression of miRNAs was compared between CIN2 --3 and SCCs with a gain or loss of the respective miRNA gene locus and samples without this chromosomal alteration using IntCNGEAn. 32 Only miRNAs located at chromosomal alterations occurring in at least 30% of samples were included (n ¼ 81). IntCNGEAn analysis identified five miRNAs that also showed significantly differential expression in CIN2 --3/SCC compared with normal epithelium (printed in bold in Table 1a ). For hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32) and hsa-miR-28-5p (3q27.3) the significantly increased expression found was associated with the presence of a chromosomal gain, whereas for hsa-miR-100 and hsa-miR-125b (both 11q24.1) the significantly decreased expression was related to a chromosomal loss. To validate these results we re-analysed the expression of the five identified miRNAs in 30 of 47 samples analysed by array using qRT--PCR. Increased expression of hsa-miR-9, hsa-miR-15b and hsa-miR-28-5p was found in samples with a gain of 1q (hsa-miR-9; P ¼ 0.09) or 3q (hsa-miR-15b; P ¼ 0.08 and hsa-miR-28-5p; P ¼ 0.03) (Supplementary Figures 3A --C). Decreased expression of hsa-miR-100 and hsamiR-125b in samples with a loss of 11q was also observed by qRT--PCR, but was not significant (hsa-miR-100; P ¼ 0.27 and hsa-miR125b; P ¼ 0.30), which might be partly due to the small number of samples with a loss of 11q tested (n ¼ 9) (Supplementary Figures 3D and E).
Functional involvement of hsa-miR-9 in vitro
We found increased expression of hsa-miR-9 in cervical cancer to be associated with a gain of chromosome 1q, suggesting that hsa- microRNA expression profiling of cervical cancer SM Wilting et al miR-9 could serve as an oncogene in hrHPV-mediated carcinogenesis. The oncogenic potential of hsa-miR-9 was determined in the HPV16-immortalised keratinocyte cell line FK16A, as endogenous hsa-miR-9 expression was found to increase from early to latepassages of this cell line (data not shown). Ectopic expression of hsa-miR-9 in early-passage FK16A cells (Figure 3a ) increased cell viability (Figure 3b ; Po0.01), anchorageindependent growth (Figures 3c and d) and migration (Figure 3e ), whereas no effect on invasion was found (Figure 3f ). In addition, ectopic expression of hsa-miR-9 in SiHa cells with already high endogenous hsa-miR-9 expression further increased the cell viability of SiHa cells as well, indicating that hsa-miR-9 expression levels are not yet saturated in SiHa cells and confirming the beneficial effect of high levels of hsa-miR-9 expression in hrHPVtransformed cells (Supplementary Figures 4A and B) .
Transient knockdown of hsa-miR-9 in late-passage FK16A cells (Figure 4a ) decreased cell viability (Figure 4b ; Po0.01) and anchorage-independent growth (Figures 4c and d) , but did not alter migratory and invasive capacity (Figures 4e and f) . Knockdown of the endogenously already low hsa-miR-9 expression in early-passage FK16A did not alter cellular viability, confirming that these cells are not yet dependent on hsa-miR-9 expression (Supplementary Figures 4C and D) .
Finally, organotypic raft cultures of early-passage FK16A cells stably expressing hsa-miR-9 were performed to investigate the potential effect of hsa-miR-9 on differentiation. As shown in Figure 5 , overexpression of hsa-miR-9 in early-passage FK16A hampered epithelial differentiation, as reflected by decreased protein expression of cytokeratin 10 (KRT10) (Figures 5d --f) . This reduction in differentiation was accompanied by an increased number of proliferating cells throughout all strata of the epithelium, including the superficial cell layers, as indicated by positivity for the proliferation-related Ki-67 antigen (MKI67) (Figures 5g --i) . The latter is in line with cell viability results (Figure 3b) . Unfortunately, raft culture experiments could not be performed with late-passage FK16A with knockdown of hsa-miR-9 expression, due to the transient nature of the knockdown.
DISCUSSION
In this study, we investigated alterations in miRNA expression during cervical carcinogenesis in relation to chromosomal instability. To avoid the identification of miRNA alterations strictly related to the presence of hrHPV and favour the identification of miRNAs contributing to the transformation process following hrHPV infection, we chose to use hrHPV-positive normal cervical epithelium for our comparisons.
For 106 miRNAs, significantly differential expression was observed in the histological categories of specimens representing microRNA expression profiling of cervical cancer SM Wilting et al the consecutive stages of cervical SCC development. Further validating our results, 30 of these miRNAs showed concordant differential expression in previous studies investigating miRNA expression mainly in cervical carcinomas. 18,20 --23 The inclusion of CIN2 --3 lesions allowed us to discern distinct expression patterns in the total group of differentially expressed miRNAs. Twentyseven miRNAs showed differential expression only in CIN2 --3 compared with normal and were therefore designated as 'early transient'. This wavy expression pattern may indicate temporal involvement in cervical cancer development, involvement in the defence mechanisms against this transformation process, or that changed expression of these miRNAs merely represents a consequence of the change in phenotype. Previous studies investigating cervical and bronchial precancerous lesions also encountered this phenomenon. 23, 33 Of 46 miRNAs, differential expression was restricted to SCCs, suggesting these miRNAs are potentially important for the progression of high-grade CIN lesions towards invasive carcinomas. Finally, 33 miRNAs showed concordant differential expression in both CIN2 --3 and SCCs.
DIGMAP identified four chromosomal loci displaying differential miRNA expression between CIN2 --3/SCCs and normal epithelium (9q22.33, 13q31.3, 14q32.1 --32.32 and Xq26.2 --26.3). As DIGMAP uses a sliding window approach rendering the analysis more powerful, not all miRNAs located within the identified loci showed significantly differential expression at the single miRNA level. Except for the locus at chromosome 13, these loci are not frequently altered on the chromosomal level. However, it is likely that expression of clustered miRNAs (located within 10 kb of each other) is controlled in a similar manner due to the presence of shared regulatory sequences and the formation of polycistronic primary miRNAs. The identified locus on 13q contains a wellknown cluster of onco-miRs (17 --92 cluster). Expression of this cluster was found to be increased by DIGMAP analysis despite a frequent chromosomal loss of this locus in cervical cancer. As expression of this cluster of miRNAs was shown to be regulated by the E2F family of transcription factors, 34 overexpression of this cluster in cervical cancer might be due to the presence of the viral oncoprotein E7, which induces continuous activation of E2F.
A direct relation between chromosomal alterations and significantly differential miRNA expression was found for five miRNAs (hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1)) using an objective statistical method including multiple testing correction (IntCNGEAn). Decreased expression of hsa-miR-100 and hsamiR-125b related to a chromosomal loss of 11q has also been found in oral cancer and altered expression of these miRNAs was shown to be functionally involved in carcinogenesis in vitro. 35 For hsa-miR-9 contradictory results have been reported, which may in part be related to the fact that hsa-miR-9 is present at three chromosomal locations in the human genome (at chromosomes 1, 5, and 15). Whereas all three loci give rise to the same mature miRNA sequence, the primary miRNA transcripts are different. Elevated copy numbers of the hsa-mir-9-1 locus (1q), as we found in cervical (pre)cancer, were also described in ovarian cancer, breast cancer and melanoma. 27 In ovarian cancer, despite the frequent presence of elevated copy numbers for hsa-mir-9-1, decreased expression of hsa-miR-9 was found in a small set of ovarian cancers with unknown chromosomal status compared with matched normal and ectopic hsa-miR-9 expression repressed cell growth in vitro. 36 In breast cancer, increased expression of the hsa-mir-9-1 primary transcript was found compared with normal breast, whereas a decrease in the expression of primary transcript hsa-mir-9-3 (15q) was found in breast tumours with lymph node metastasis and in tumours with vascular invasion compared with tumours without these characteristics. 37 This latter finding is supported by the significant association between methylation at the hsa-mir-9-3 locus and lymph node metastasis in breast cancer, lung cancer and melanoma and increased risk of recurrence in clear-cell renal cell carcinomas. 38, 39 In addition, it was shown that epigenetic silencing of hsa-mir-9-3 reduced p53-mediated apoptosis in mammosphere-derived breast epithelial cells. 40 Methylation of the hsa-mir-9-1 locus has been described in clear-cell renal cell carcinomas, breast cancer and pre-invasive intraductal lesions of the breast as well, but expression levels in these tumours were not related to the expression levels in corresponding normal tissue. 38, 41 In our study, increased expression of hsa-miR-9 related to a chromosomal gain of the hsa-mir-9-1 locus was found in cervical (pre)cancerous lesions compared with normal epithelium. To confirm the results of our integration analysis, we specifically determined the expression of the primary transcript hsa-mir-9-1 (derived from the locus on 1q) in four SCCs with a 1q gain and four SCCs without this chromosomal alteration and found a 2.4-fold higher expression in the SCCs with a 1q gain (data not shown). Ectopic expression of hsa-miR-9 in early-passage HPV16-immortalised cells with low levels of endogenous hsa-miR-9 resulted in an increase in the cell viability, anchorage-independent growth and migration. Vice versa, knockdown of hsa-miR-9 expression in a later passage of the same cell line, showing elevated endogenous hsa-miR-9 levels, decreased cell viability and anchorage-independent growth. Moreover, upon organic raft culturing hsa-miR-9 overexpression reduced epithelial differentiation, accompanied by an increased number of proliferating cells throughout all strata of the epithelium. These findings suggest a putative role for hsa-miR-9 in the switch from differentiation to proliferation during hrHPV-mediated transformation of squamous epithelial cells.
Together, our results point to an oncogenic role of hsa-miR-9 in the context of hrHPV-induced malignant transformation. Interestingly, Hu et al. 17 showed that relatively high levels of hsa-miR-9 expression in a group of cervical carcinoma patients was associated with a better overall survival rate, potentially indicating better treatment response due to high hsa-miR-9 expression.
In this study, we found evidence that chromosomal alterations may be directly involved in the altered expression of part of the miRNAs associated with cervical carcinogenesis. However, recent literature suggests that other mechanisms, including epigenetic alterations, appear highly important as well. It is now estimated suggesting that DNA methylation may have a prominent role in (ab)normal miRNA expression. In this study nine out of the 43 (21%) significantly downregulated miRNAs were located within a CpG island. We found preliminary evidence of methylation-mediated silencing for three of these nine miRNAs, hsa-miR-203, hsa-miR-572 and hsa-miR-638 in a panel of hrHPV-transformed cell lines (data not shown). Promoter methylation of hsa-miR-203 has already been described in hepatocellular carcinoma, oral cancer, cervical cancer and haematopoietic malignancies, 43 --47 whereas, to the best of our knowledge, methylation-mediated silencing of hsa-miR-572 and hsa-miR-638 has not been previously described in cancer. Based on the foregoing information, further investigations regarding methylation-mediated silencing of miRNAs and its functional relevance during hrHPV-mediated transformation are warranted.
In conclusion, this study showed that changes in miRNA expression in cervical (pre)malignant lesions are partly associated with chromosomal alterations. In addition, the data presented here provide valuable insights in the distinct expression profiles of miRNAs during the different stages of cervical cancer development. Integration of miRNA expression profiles with chromosomal alterations resulted in the identification of hsa-miR-9 as a candidate oncogene in cervical cancer, which may represent a promising disease marker, as well as a potential therapeutic target. Together, the findings of this study underline the importance of deregulated miRNA expression in cervical cancer development.
MATERIALS AND METHODS
Clinical tissue specimens and HPV testing
For miRNA microarray analysis we used frozen specimens of 10 SCCs, 9 AdCAs, 18 CIN2 --3 and 10 cervical squamous epithelial samples with normal histology (Supplementary Table 1 ). Only CIN2 --3 showing strong diffuse p16
INK4A staining by immunohistochemistry were included, as p16 INK4A overexpression is a marker for CIN2 --3 lesions that harbour a transforming hrHPV infection and are considered the true precursor lesions of cervical cancer. 48 Genome-wide chromosomal profiles of all SCC and CIN2 --3 samples were previously generated using array-based comparative genomic hybridisation (array CGH). 29, 30 hrHPV testing on all specimens was performed using GP5 þ /6 þ -PCR with enzyme immunoassay read-out using a probe cocktail of 14 hrHPV types. 49 Of the samples analysed by miRNA microarray, all samples except for one normal sample contained hrHPV (Supplementary Table 1 ). All biopsy samples were collected during the course of routine clinical practice at the Department of Obstetrics and Gynaecology at the VU University Medical Center (Amsterdam). This study followed the ethical guidelines of the Institutional Review Board of the VU University Medical Center.
Cell lines
Establishment and culture of FK16A, an HPV16 immortalised keratinocyte cell line, was described previously. 50 The human cervical carcinoma cell line SiHa was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as described previously. Tissue samples were first subjected to laser capture microdissection using a Leica ASLMD microscope (Leica, Heidelberg, Germany) to enrich for neoplastic, dysplastic or normal epithelial cells as described previously. 52 Total RNA was isolated from microdissected tissue samples using TRIzol Reagent (Life Technologies, Breda, The Netherlands) according to the manufacturer's instructions. To ensure comparable RNA integrity between specimens analysed by array, RNA pico chips were performed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).
MiRNA microarrays
Global miRNA expression profiles were determined using human miRNA microarrays (G4471A-016436, Agilent Technologies, Santa Clara, CA, USA). These arrays contain in situ synthesised 60-mer oligonucleotides representing 472 human miRNAs (MiRbase release 9.1). Labelling and hybridisation was performed according to the manufacturers' instructions. MiRNA and CGH microarray data are available from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) through series accession numbers GSE11573 (CGH data CIN2 --3 lesions), GSE6473 (CGH data SCCs) and GSE30656 (miRNA expression profiles of all samples).
Microarray analysis
Data pre-processing. The obtained single-channel microarray data were log-transformed and normalised using quantile normalisation. Probes with log2 intensities below 6 (corresponding to intensity below 64) in more than 90% of the samples were discarded (n ¼ 44).
Cluster analysis. Unsupervised hierarchical clustering analysis was performed on all probes that met our quality criteria using the Manhattan distance measure and Ward's linkage.
Differential miRNA expression analysis. Differentially expressed miRNAs were determined using the Wilcoxon two-sample test. The test procedure includes a permutation-based FDR correction for multiple testing, needed to discriminate real differences from chance effects. 53 An FDR below 0.05 was considered significant. DIGMAP analysis. Differential gene locus mapping (DIGMAP) analysis was carried out in the CIN2 --3 and SCCs to investigate aberrant expression patterns of groups of miRNAs based on their chromosomal location as previously described. 52, 54 With this technique, changes in expression associated with the chromosomal location can be detected and related to chromosomal alterations, as well as other mechanisms, such as shared regulatory sequences. Statistically significant loci were identified using the T-test, which generates confidence (T) scores by log-transformation of the reciprocal P-value. An automated scanning method employing sliding window analysis was used to find so-called differential flag regions. In this analysis, a sliding window size of 10 was used and regions with a T score greater than two standard deviations from the mean of total T scores for all windows were considered as differentially flagged regions (DFR).
Integrated copy number and gene expression analysis (IntCNGEAn).
MiRNA expression levels were directly linked to the underlying chromosomal copy number of the miRNA as measured by array CGH using integrated copy number and gene expression analysis (IntCNGEAn). 32 miRNAs and BAC clones were positioned along the genome using the GRCh 37 freeze. Matching of copy number data and miRNA expression data was performed using the method 'distance', in which the midpoint of the copy number and miRNA expression features are calculated and for each miRNA the closest copy number feature (BAC clone) is selected. Only miRNAs that are located on a chromosomal location that was altered in at least 30% of SCCs and CIN2 --3 together were tested (81 miRNAs). The Figure 5 . Organotypic raft cultures of FK16A early with and without ectopic hsa-miR-9 expression. Representative pictures of H&E staining are shown for the raft cultures of (a) parental early FK16A rafts, (b) FK16A early þ ctrl rafts, and (c) FK16A early þ miR-9 rafts. Immunohistochemical staining patterns for the differentiation marker cytokeratin 10 (KRT10) are shown in (d) parental early FK16A rafts, (e) FK16A early þ ctrl rafts and (f ) FK16A early þ miR-9 rafts. Similarly, protein expression patterns of the proliferation-related Ki-67 antigen (MKI67) are shown in (g) parental early FK16A rafts, (h) FK16A early þ ctrl rafts and (i) FK16A early þ miR-9 rafts.
statistical test performed was a one-tailed weighted Mann --Whitney test. P-values are calculated via permutation. The P-values are corrected for multiplicity by the Benjamini --Hochberg procedure. miRNAs with an FDR below 0.2 and concordant significant differential expression between CIN2 --3 and/or SCCs and normal epithelium were considered significant.
Quantitative reverse transcription--PCR
Expression of hsa-miR-9, hsa-miR-15b, hsa-miR-21, hsa-miR-28-5p, hsa-miR-100, hsa-miR-125b, hsa-miR-203 and hsa-miR-375 was measured using TaqMan miRNA assays following the manufacturer's instructions (000583, 00390, 000397, 00411, 00437, 00449, 000507, 000564; Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) on the ABI 7500 Fast Real-Time PCR System (Applied Biosystems). The small nucleolar RNA transcript RNU43 was included as a reference gene (001095; Applied Biosystems). miRNA expression values were normalised to the reference using the comparative CT method (2 ÀDCT ). 55 
Retroviral transduction
For the transduction experiments, early-passage FK16A cells (p61) and SiHa cells were incubated for 4 and 16 h, respectively, at 37 1C with filtered viral supernatants supplemented with polybrene (15 mg/ml). 56 FK16A/SiHa_miR9 and FK16A/SiHa_ctrl cells were selected by continuous culturing of the transduced cells in the presence of blasticidin (2 mg/ml) and ectopic overexpression was verified by qRT--PCR analysis.
AntagomiR transfection
Late-passage FK16A cells (Bp200) were transiently transfected with 25 nM mirCURY LNA microRNA power Inhibitor for hsa-miR-9 or negative control A (427460-04 and 199020-04, respectively, Exiqon, Vedbaek, Denmark), using Lipofectamin 2000 Reagent according to the manufacturer's instructions. Knockdown efficacy was verified by qRT--PCR analysis.
Cell viability assay
Cell viability was measured using a colorimetric (MTT --tetrazolium) assay (MP Biomedicals, Illkrich, France) as described before. 57, 58 The proliferation rate was determined by subtracting the measurement of day 0 from all other time points.
Colony formation in soft agar
Anchorage-independent cell growth was analysed as described before. 59 Colonies were photographed and counted after 3 weeks of incubation.
Cellular migration and invasion
Migration and invasion were determined using transwells containing a fluorescence blocking filter (HTS FluoroBlok; Falcon, BD Biosciences, Breda, The Netherlands). For migration assays the transwell was left uncoated, whereas for invasion assays the transwell was coated with collagen (50 mg/ ml solution in PBS; Collagen Type I rat tail, BD Biosciences). In all cases the bottom of the transwell was coated with fibronectin (2 mg/ml solution in PBS; MP Biomedicals). Cells in medium without supplements were added to the top compartment, whereas complete medium was added to the bottom compartment of the transwell. Migration or invasion was quantified after 48 h by fluorescent labelling of the cells using calcein-AM (Molecular Probes, Invitrogen, Leiden, The Netherlands). To determine the relative amount of cells that either migrated or invaded through the transwell, ratios between the fluorescence intensities of the bottom and top compartment were calculated.
Organotypic raft cultures and immunohistochemistry FK16A cells were grown as epithelial raft tissues as described previously. 60 For all conditions duplicate rafts were developed. After 8 days the raft tissues were fixed in formalin and embedded in paraffin. For histological examination, 4 mM sections were stained with haematoxylin and eosin. In addition, immunohistochemical staining was performed for differentiation marker cytokeratin 10 and proliferation-related Ki-67 antigen (MKI67).
Slides were incubated with 0.3% H 2 O 2 in methanol to inhibit endogenous peroxidase. Antigen retrieval was performed by boiling the slides in a microwave oven either in citrate buffer (10 mM, pH 6.0) for cytokeratin 10 (LHP1, dilution 1:100, Novocastra, Leica Biosystems, Newcastle, UK) or Tris/ EDTA buffer (10 mM, pH9) for MIB1 (MIB-1, dilution 1:40, DakoCytomation, Glostrup, Denmark). Slides were incubated with the monoclonal antibody for 1 h at room temperature. For antibody detection the EnVision horseradish peroxidase system (Dako, Glostrup, Denmark) was used. Sections were counterstained with haematoxylin.
Statistical analysis
The non-parametric Spearman's rank correlation was determined between array and qRT--PCR results. Expression levels of miRNAs as measured by qRT--PCR were compared between samples with and without the associated chromosomal alteration using the non-parametric two-sample Wilcoxon test (one-tailed). Proliferation rates between cell lines were compared using the Student's t-test.
